Journal Article

Risk of subsequent gliomas and meningiomas among 69,460 5-year survivors of childhood and adolescent cancer in Europe: the PanCareSurFup study

de Vathaire, Florent, Michel, Gisela, Garwicz, Stanislaw, Kok, Judith L., Hjorth, Lars, Schindera, Christina, Terenziani, Monica, Kaatsch, Peter, Haddy, Nadia, Heymer, Emma J., Bárdi, Edit, Belle, Fabiën N., Skinner, Roderick, Maule, Milena M., Winther, Jeanette F., Kremer, Leontien C., Sunguc, Ceren, Byrne, Julianne, Zadravec Zaletel, Lorna, Ronckers, Cécile M., Bagnasco, Francesca, Haupt, Riccardo, Reulen, Raoul C., Allodji, Rodrigue S., Alessi, Daniela, Jakab, Zsuzsanna, Jankovic, Momcilo, Česen Mazić, Maja, Grabow, Desiree, Kaiser, Melanie, Journy, Neige, Winter, David L., Lähteenmäki, Päivi M., Wiebe, Thomas, Kuehni, Claudia E., Sugden, Elaine, Sacerdote, Carlotta, Teepen, Jop C., Gunnes, Maria W., Hawkins, Michael M.

2024

Overview

Background Childhood cancer survivors are at risk of subsequent gliomas and meningiomas, but the risks beyond age 40 years are uncertain. We quantified these risks in the largest ever cohort. Methods Using data from 69,460 5-year childhood cancer survivors (diagnosed 1940–2008), across Europe, standardized incidence ratios (SIRs) and cumulative incidence were calculated. Results In total, 279 glioma and 761 meningioma were identified. CNS tumour (SIR: 16.2, 95% CI: 13.7, 19.2) and leukaemia (SIR: 11.2, 95% CI: 8.8, 14.2) survivors were at greatest risk of glioma. The SIR for CNS tumour survivors was still 4.3-fold after age 50 (95% CI: 1.9, 9.6), and for leukaemia survivors still 10.2-fold after age 40 (95% CI: 4.9, 21.4). Following cranial radiotherapy (CRT), the cumulative incidence of a glioma in CNS tumour survivors was 2.7%, 3.7% and 5.0% by ages 40, 50 and 60, respectively, whilst for leukaemia this was 1.2% and 1.7% by ages 40 and 50. The cumulative incidence of a meningioma after CRT in CNS tumour survivors doubled from 5.9% to 12.5% between ages 40 and 60, and in leukaemia survivors increased from 5.8% to 10.2% between ages 40 and 50. Discussion Clinicians following up survivors should be aware that the substantial risks of meningioma and glioma following CRT are sustained beyond age 40 and be vigilant for symptoms.

• Publisher: Nature Publishing Group UK,Nature Publishing Group
• Subject: 631/67/1922 / 631/67/2324 / 631/67/2332 / 692/308/174 / 692/499 / Adolescent / Adult / Age / Biomedical and Life Sciences / Biomedicine / Brain cancer / Cancer / Cancer and Oncology / Cancer och onkologi / Cancer Research / Central Nervous System Neoplasms - epidemiology / Childhood / Children / Clinical Medicine / Drug Resistance / Epidemiology / Europe - epidemiology / Glioma / Glioma - epidemiology / Humans / Incidence / Klinisk medicin / Leukemia / Leukemia - epidemiology / Medical and Health Sciences / Medicin och hälsovetenskap / Meningeal Neoplasms - epidemiology / Meningioma / Meningioma - complications / Meningioma - etiology / Middle Aged / Molecular Medicine / Neoplasms, Second Primary - epidemiology / Neoplasms, Second Primary - etiology / Oncology / Radiation therapy / Risk Factors / Survivor / Survivors / Teenagers / Tumors